

- III. Claim 9, drawn to an antibody, classified in class 530, subclass 387.1.
- IV. Claims 10-25, drawn to a method of modulating angiogenesis, classified in class 514, subclass 2.
- V. Claims 26-27, drawn to a method of determining whether a compound up-regulates or down-regulates transcription, classified in class 436, subclass 94.
- VI. Claims 28-29, drawn to a method of determining whether a compound up-regulates or down-regulates translation, classified in class 436, subclass 500.
- VII. Claims 32-34, and 40, drawn to a method of screening tissue sample for tumorigenic potential, classified in class 436, subclass 94.
- VIII. Claims 35-39, drawn to a transgenic animal, classified in class 800, subclass 18.
- IX. Claim 41, drawn to method of determining the clinical stage of tumor, classified in class 436, subclass 94.

Applicants elect, with traverse, Group I, Claims 1-4. As a species election,  
Applicants elect SEQ ID NO (4); all the elected claims read on this species.

*elects 4  
as part of  
invention*